Long-Term Dividend-Paying Stocks to Invest in for a Decade

Stocks with Dividends to Keep for the Following Decade

In the second quarter of 2023, biopharmaceutical giant Amgen reported a significant 9% year-over-year increase in revenue, reaching $9.2 billion. This growth was driven by the strong performance of several of its key products, including Repatha, Tezspire, and Evenity.

However, Amgen faces challenges ahead, as patent cliffs loom for two of its products, Prolia and Xvegia, with the former set to expire this year and the latter in the future. To counteract this, Amgen has a robust pipeline of products expected to receive approval, which could help it navigate these patent cliffs.

One of Amgen's upcoming products is bemarituzumab, which showed positive results in a phase 3 clinical trial for the treatment of gastric cancer. This promising development could further bolster Amgen's product portfolio.

Meanwhile, in the field of weight loss medicines, Amgen and Eli Lilly are making strides. Novo Nordisk, another major player, is anticipating the approval of Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) primarily in the United States in the coming months. The US FDA has already granted approval for this new indication, but specific information about other countries expecting approval is not currently available.

Amgen's status as a strong dividend stock is well-established, with a 3.2% yield and a 185% dividend increase over the past decade. This makes Amgen a top income stock to hold through the next decade, according to analysts.

Furthermore, Amgen's investigational weight loss medicine, MariTide, could potentially generate $3.7 billion in revenue by 2030. This promising prospect underscores Amgen's commitment to innovation and growth in the pharmaceutical industry.

In conclusion, while Amgen faces challenges with patent cliffs for some of its products, its robust pipeline, strong dividend, and promising new products position it well for the future. The company remains a significant player in the pharmaceutical industry, particularly in the fields of oncology and weight loss medicines.